GlassScriptPhysician profile
Taylor N Pedersen
NPI 1043740202
$3,933.76
in general payments reported to CMS, 2019-2025
30 companies · $585 in 2025
The $585 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $297 · 2021: $734 · 2022: $588 · 2023: $1,092 · 2024: $639 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831 · Travel and Lodging: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.59 |
| Travel and Lodging | $485.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $582.59 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Henry Schein, INC. | $485.19 | 2023 | |
| Lilly USA, LLC | $370.62 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $352.30 | 2021-2025 | |
| Abbvie INC. | $293.67 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $259.73 | 2020-2025 | Gardasil 9, Vaxelis, Gardasil |
| Novo Nordisk INC | $240.50 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $146.55 | 2020-2023 | Arexvy |
| Amgen INC. | $132.56 | 2020-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $132.22 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.83 | 2020-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $109.02 | 2020-2025 | Rexulti, Abilify Maintena |
| Organon LLC | $99.98 | 2021-2023 | Nexplanon |
| Globus Medical, INC. | $94.28 | 2025 | Senza |
| Astellas Pharma US INC | $81.27 | 2021-2025 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.43 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $46.30 | 2025 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $43.36 | 2020-2024 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $41.06 | 2022 | |
| Lundbeck LLC | $34.91 | 2024 | Rexulti |
| Exact Sciences Corporation | $28.97 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $28.56 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.75 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.22 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $19.98 | 2022 | |
| Dexcom, INC. | $18.78 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $17.86 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.36 | 2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $12.38 | 2021 | |
| Allergan, INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Pedersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.